このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Merck KGaA 将来の成長

Future 基準チェック /16

Merck KGaA利益と収益がそれぞれ年間11.3%と4.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に14.1% 11.5%なると予測されています。

主要情報

11.4%

収益成長率

11.5%

EPS成長率

Pharmaceuticals 収益成長	21.5%
収益成長率	4.8%
将来の株主資本利益率	14.1%
アナリストカバレッジ	Good
最終更新日	25 Jun 2024

今後の成長に関する最新情報

Recent updates

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Mar 26

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Mar 05

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Feb 14

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Dec 12

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Nov 09

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Aug 15

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

May 17

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Mar 29

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Jan 13

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

Oct 15

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Sep 19

MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Seems To Use Debt Quite Sensibly

Jul 11

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 21

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Apr 03

Do Institutions Own MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Shares?

Mar 16

業績と収益の成長予測

XTRA:MRK - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	23,848	3,933	3,516	5,518	12
12/31/2025	22,641	3,524	3,078	5,062	14
12/31/2024	21,324	2,994	2,863	4,810	14
3/31/2024	20,820	2,722	1,961	3,966	N/A
12/31/2023	20,993	2,824	1,897	3,784	N/A
9/30/2023	21,428	2,893	1,912	3,746	N/A
6/30/2023	22,061	3,078	2,198	4,042	N/A
3/31/2023	22,327	3,242	2,334	4,272	N/A
12/31/2022	22,232	3,326	2,491	4,259	N/A
9/30/2022	21,785	3,473	2,788	4,289	N/A
6/30/2022	20,952	3,311	2,658	4,204	N/A
3/31/2022	20,254	3,188	2,734	4,240	N/A
12/31/2021	19,687	3,055	3,234	4,616	N/A
9/30/2021	19,072	2,689	3,125	4,859	N/A
6/30/2021	18,546	2,733	3,073	4,562	N/A
3/31/2021	17,795	2,278	2,702	4,177	N/A
12/31/2020	17,534	1,987	2,002	3,477	N/A
9/30/2020	17,317	1,884	1,684	2,879	N/A
6/30/2020	16,924	1,419	1,498	2,640	N/A
3/31/2020	16,776	1,549	1,729	2,879	N/A
12/31/2019	16,152	1,292	1,858	2,856	N/A
9/30/2019	15,658	1,139	1,967	2,906	N/A
6/30/2019	15,354	1,118	1,751	2,706	N/A
3/31/2019	15,096	938	1,425	2,332	N/A
12/31/2018	14,836	1,071	1,270	2,219	N/A
9/30/2018	14,597	1,921	1,031	2,120	N/A
6/30/2018	14,364	2,218	1,053	2,147	N/A
3/31/2018	14,346	2,389	1,157	2,299	N/A
12/31/2017	14,517	2,548	N/A	2,696	N/A
9/30/2017	14,699	1,787	N/A	2,842	N/A
6/30/2017	14,906	1,628	N/A	3,152	N/A
3/31/2017	15,016	1,529	N/A	2,943	N/A
12/31/2016	15,024	1,629	N/A	2,518	N/A
9/30/2016	14,658	1,480	N/A	2,449	N/A
6/30/2016	14,054	1,387	N/A	2,253	N/A
3/31/2016	13,469	1,418	N/A	2,268	N/A
12/31/2015	12,845	1,109	N/A	2,195	N/A
9/30/2015	12,380	1,269	N/A	2,618	N/A
6/30/2015	12,180	1,154	N/A	2,472	N/A
3/31/2015	11,776	1,114	N/A	2,576	N/A
12/31/2014	11,363	1,157	N/A	2,706	N/A
9/30/2014	11,106	1,158	N/A	2,005	N/A
6/30/2014	10,937	1,249	N/A	2,105	N/A
3/31/2014	10,963	1,261	N/A	2,119	N/A
12/31/2013	11,095	1,202	N/A	2,226	N/A
9/30/2013	11,188	1,193	N/A	2,183	N/A
6/30/2013	11,277	1,039	N/A	2,265	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MRKの予測収益成長率 (年間11.3% ) は貯蓄率 ( 0.7% ) を上回っています。

収益対市場: MRKの収益 ( 11.3% ) German市場 ( 18.6% ) よりも低い成長が予測されています。

高成長収益: MRKの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: MRKの収益 ( 4.8% ) German市場 ( 5.1% ) よりも低い成長が予測されています。

高い収益成長: MRKの収益 ( 4.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MRKの自己資本利益率は、3年後には低くなると予測されています ( 14.1 %)。

Merck KGaA 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Price target increased to €195

Price target increased to €170

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Recent updates

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Upcoming dividend of €2.20 per share

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price

Investor sentiment deteriorates as stock falls 15%

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?

Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

Is Merck KGaA (ETR:MRK) A Risky Investment?

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Full year 2022 earnings: Revenues in line with analyst expectations

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2022 Results on Aug 04, 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Third quarter 2021 earnings released

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Price target increased to €195

Price target increased to €170

Second quarter 2021 earnings released: EPS €1.71 (vs €0.67 in 2Q 2020)

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company